Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.

ABSTRACT: Background: Interstitial lung disease (ILD) is a common pulmonary disease often associated with significant morbidity and mortality in patients with connective tissue diseases (CTD). Currently, no gold-standard therapies are available for CTD-ILD. Recently, several studies have proposed that rituximab (RTX) may be effective for the treatment of CTD-ILD. Objectives: This study aimed to systematically evaluate the efficacy and safety of RTX for the treatment of CTD-ILD. Methods: Studies were selected from PubMed, Embase, and Cochrane Library, up to 20 July 2022. Improvement and stable rates were extracted as the main outcomes and pooled using the weighted mean proportion with fixed or random-effects models, in case of significant heterogeneity (I ²

SUBMITTER: Xu L 

PROVIDER: S-EPMC9650441 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature